--- title: "Nexalin Technology (NXL) stock: news and investor profile" url: "https://aibio.space/companies/nexalin-technology/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Nexalin Technology, Inc. (NASDAQ: NXL), United States. Listing facts, related biotech companies and news on aibio.space." --- NXL Nexalin Technology, Inc. NASDAQ · United States # Nexalin Technology (NXL) news Debt Financing · 2026-08-21 ## [Nexalin issues $1,170,000.00 promissory note to Streeterville Capital](https://aibio.space/news/nexalin-issues-1-170-000-00-promissory-note-streeterville-capital/) The unsecured note carries a $150,000.00 original issue discount and a $20,000.00 transaction expense amount. The purchase price is $1,000,000.00, and the lender is Streeterville Capital, LLC. ## Latest Nexalin Technology news We have not published a story on Nexalin Technology yet. When there is news, it will appear here. ## Nexalin Technology at a glance - **Ticker**: NXL - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $1.0 million ### Related companies - [CYANOTECH CORP](https://aibio.space/companies/cyanotech/) OTC: CYAN - [PRO DEX INC](https://aibio.space/companies/pro-dex/) NASDAQ: PDEX - [Neuraxis, INC](https://aibio.space/companies/neuraxis/) NYSE: NRXS - [Enovis CORP](https://aibio.space/companies/enovis/) NYSE: ENOV - [SHOULDER INNOVATIONS, INC.](https://aibio.space/companies/shoulder-innovations/) NYSE: SI - [Envista Holdings](https://aibio.space/companies/envista/) NYSE: NVST - [Co-Diagnostics](https://aibio.space/companies/diagnostics/) NASDAQ: CODX - [IQVIA HOLDINGS INC.](https://aibio.space/companies/iqvia/) NYSE: IQV ### Also on NASDAQ - [BillionToOne](https://aibio.space/companies/billiontoone/) BLLN - [ABVC BioPharma](https://aibio.space/companies/abvc-biopharma/) ABVC - [Q32 Bio](https://aibio.space/companies/q32-bio/) QTTB - [Innovative Eyewear](https://aibio.space/companies/innovative-eyewear/) LUCY - [Research Alliance Corp III](https://aibio.space/companies/research-alliance-iii/) RACC - [Verrica Pharmaceuticals](https://aibio.space/companies/verrica-pharmaceuticals/) VRCA ## Nexalin Technology annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$301,647](https://www.sec.gov/Archives/edgar/data/1527352/000182912626002673/) | [$168,721](https://www.sec.gov/Archives/edgar/data/1527352/000182912626002673/) | | Research and development | [$1.1 million](https://www.sec.gov/Archives/edgar/data/1527352/000182912626002673/) | [$1.2 million](https://www.sec.gov/Archives/edgar/data/1527352/000182912626002673/) | | Net income (loss) | [-$8.2 million](https://www.sec.gov/Archives/edgar/data/1527352/000182912626002673/) | [-$7.6 million](https://www.sec.gov/Archives/edgar/data/1527352/000182912626002673/) | | Cash from operations | [-$5.0 million](https://www.sec.gov/Archives/edgar/data/1527352/000182912626002673/) | [-$3.9 million](https://www.sec.gov/Archives/edgar/data/1527352/000182912626002673/) | | Cash and equivalents | [$654,783](https://www.sec.gov/Archives/edgar/data/1527352/000182912626008709/) | [$574,485](https://www.sec.gov/Archives/edgar/data/1527352/000182912626002673/) | | Short-term investments | [$3.1 million](https://www.sec.gov/Archives/edgar/data/1527352/000182912626008709/) | [$2.9 million](https://www.sec.gov/Archives/edgar/data/1527352/000182912626002673/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $1.0 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Nexalin Technology What is the ticker symbol of Nexalin Technology? Nexalin Technology, Inc. trades under the ticker NXL on NASDAQ. Where is Nexalin Technology listed? Nexalin Technology, Inc. is listed on NASDAQ. Which country or territory is Nexalin Technology listed under? Our directory records Nexalin Technology, Inc. under United States. Does aibio.space cover Nexalin Technology? aibio.space lists Nexalin Technology, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. What was Nexalin Technology's revenue last year? $301,647 for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Nexalin Technology profitable? Nexalin Technology, Inc. reported a net loss of $8.2 million for the fiscal year ended Dec 31, 2025, and used $5.0 million of cash in operations, per its annual report to the SEC. How much does Nexalin Technology spend on research and development? $1.1 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Nexalin Technology have? $1.0 million in cash at Jun 30, 2026, per its 10-Q. What is the latest Nexalin Technology (NXL) stock news? Our latest story on Nexalin Technology, dated Aug 21, 2026: "Nexalin issues $1,170,000.00 promissory note to Streeterville Capital". The unsecured note carries a $150,000.00 original issue discount and a $20,000.00 transaction expense amount. The purchase price is $1,000,000.00, and the lender is Streeterville Capital, LLC. [Source](https://aibio.space/news/nexalin-issues-1-170-000-00-promissory-note-streeterville-capital/). Does Nexalin Technology have debt, a term loan or convertible notes? Our latest debt story, dated Aug 21, 2026: "Nexalin issues $1,170,000.00 promissory note to Streeterville Capital". The unsecured note carries a $150,000.00 original issue discount and a $20,000.00 transaction expense amount. The purchase price is $1,000,000.00, and the lender is Streeterville Capital, LLC. [Source](https://aibio.space/news/nexalin-issues-1-170-000-00-promissory-note-streeterville-capital/). How can I follow Nexalin Technology (NXL) news? Press Follow on this page to add Nexalin Technology to your Following list, or subscribe to the aibio.space newsletter. We have published 1 story naming Nexalin Technology so far, in Debt Financing. ## Investor discussion: Nexalin Technology Members talk about Nexalin Technology (NXL). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Nexalin Technology, newest first. Each line links the filing it comes from. 1. 2026-09-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1527352/000182912626010495/nexalintec_8k.htm) 2. 2026-08-27 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1527352/000182912626009387/nexalintec_ex99-1.htm) 3. 2026-08-17 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1527352/000182912626008934/nexalintec_8k.htm) 4. 2026-08-11 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1527352/000182912626008621/nexalintec_8k.htm) 5. 2026-07-27 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1527352/000182912626007891/nexalintec_8k.htm) 6. 2026-07-10 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1527352/000182912626007513/nexalintech_def14a.htm) 7. 2026-06-29 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1527352/000182912626007001/nexalintech_pre14a.htm) 8. 2026-05-19 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1527352/000182912626005453/nexalintec_ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:NXL on TradingView](https://www.tradingview.com/symbols/NASDAQ-NXL/). ## Listing details Nexalin Technology, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NXL, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Nexalin Technology, Inc. - **Ticker**: NXL - **Listing**: NASDAQ - **Country or territory**: United States Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/nexalin-technology/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Nexalin Technology (NXL) stock: news and investor profile", 2026-10-31, https://aibio.space/companies/nexalin-technology/